Researchers have devised and validated an 11-gene expression test that can distinguish patients with stage I or II lung cancer who have a low, intermediate, or high risk for having micrometastatic disease after primary tumor resection that requires adjuvant chemotherapy. Our reporter Mitchel Zoler asked investigator Dr. Johannes Kratz to discuss the need for and strengths of the test.
The multigene assay can outperform conventional risk factors and staging, and may lead to personalized therapies for patients with early-stage nonsquamous non–small cell lung cancer. [Dr. Krause]
You can read a more detailed analysis of the test and its implications on the IMNG Oncology Digital Network.